Attenuated Listeria monocytogenes (LM) is a promising candidate vector for the delivery of cancer vaccines. After phagocytosis by antigen-presenting cells, this bacterium stimulates the major histocompatibility complex (MHC)-I and MHC-II pathways and induces the proliferation of antigen-specific T lymphocytes. A new strategy involving genetic modification of the replication-deficient LM strain DdalDdat (Lmdd) to express and secrete human CD24 protein has been developed. CD24 is a hepatic cancer stem cell biomarker that is closely associated with apoptosis, metastasis and recurrence of hepatocellular carcinoma (HCC). After intravenous administration in mice, Lmdd-CD24 was distributed primarily in the spleen and liver and did not cause severe organ injury. Lmdd-CD24 effectively increased the number of interferon (IFN)-c-producing CD8
INTRODUCTION
Cancer and cancer-related diseases are an increasing threat to public health. Hepatocellular carcinoma (HCC), which accounts for approximately 85%-90% of primary liver cancers, is the fifth most common type of cancer and the third most common cause of cancer-related death. 1 Worldwide, 50% of HCC cases are caused by infection with the hepatitis B virus. 2 In China, where hepatitis B virus infection is prevalent, more than 100 persons per million of the Chinese population develop HCC. 3 Current therapies for this type of malignancy 4 include antiviral strategies, radiotherapy, transarterial chemoembolization and surgery, [5] [6] [7] [8] which generally do not result in a good prognosis. Early diagnosis plays a vital role in successful outcomes with these treatments. However, over 80% of HCC patients are diagnosed at advanced stages. 9 Because of the high metastasis and recurrence rates of HCC, the long-term survival of HCC patients after liver surgery is unsatisfactory. The postoperative recurrence rate is 65% with radical resection and 58% with liver transplantation. 10 Furthermore, the resistance of some HCC patients to conventional chemotherapy contributes to the poor prognosis and high mortality associated with this disease. 11 The new concept of cancer stem cells (CSCs) was recently put forward in an attempt to elucidate the mechanism of HCC chemoresistance, metastasis and recurrence. CSCs, which represent a small population of tumor cells, are capable of selfrenewal and can proliferate and differentiate into heterogeneous lines of cancer cells. 12 Hepatic CSCs were first reported by Haraguchi et al. 13 CSCs appear to arise by an epigenetic mechanism, 14 and in recent years, several important biomarkers of 22 clear cell renal carcinomas 23 and hepatocellular carcinomas. 24 Recently, Irene Oi Lin Ng, of Hong Kong University, noted that CD24 is upregulated in chemoresistant and recurrent HCC patients and that it is an important biomarker for hepatic CSCs. CD24-positive HCC cells have been shown to be critical for the maintenance, self-renewal, differentiation and metastasis of this cancer. 25 Listeria monocytogenes (LM) is a Gram-positive facultative intracellular parasite that can cause meningitis in immunocompromised individuals. 26 The bacterium can be taken up by macrophages and other phagocytic cells, primarily in the spleen and in liver Kupffer cells. Listeriolysin O, a pore-forming cytolysin encoded by the hly gene, enables the bacterium to perforate the membranes of phagocytic cells such as macrophages and dendritic cells, after which it escapes from cytoplasmic vacuoles and enters the cytoplasm. Proteins secreted by intracellular LL are degraded by proteasomes, and their constituent peptides are presented to major histocompatibility complex (MHC) class I molecules. 27 The phagocytosed foreign proteins can also be presented directly to MHC class II molecules. 28 Because this bacterium can induce both CD4 and CD8 antigen-specific immune response, it is a promising candidate as a cancer vaccine vector. However, because LM is a foodborne bacterium that can lead to meningitis in children and the elderly, attenuation of its virulence is needed for safety considerations. Two important genes are required for the construction of the cell wall of LM: alanine racemase (dal) and D-amino acid aminotransferase (dat). These two genes are essential for the synthesis of D-alanine, which is required for the construction of the mucopeptide component of the bacterial cell wall. In the absence of dal and dat expression, replication of LM can depend only on the availability of exogenous D-alanine. 29 In this study, we used an attenuated strain of L. monocytogenes referred to as replication-deficient LMDdalDdat (Lmdd) strain, from which the dal and dat genes have been deleted. After introduction of the dal and dat genes from Bacillus subtilis into the Lmdd strain, the strain was able to synthesize D-alanine and to replicate to a limited extent that did not cause severe organ injuries. The newly discovered hepatic CSC biomarker CD24 was selected as an overexpressed tumor antigen to be secreted by Lmdd. In this work, we demonstrate the safety and effectiveness of this new cancer vaccine and show that it may be useful in preventing HCC chemoresistance, metastasis and recurrence.
MATERIALS AND METHODS

Materials
The oligonucleotides and primers used in this study were synthesized by Invitrogen (Carlsbad, CA, USA). DNA sequencing was performed by Genescript Inc. (Nanjing, China). The primers to amplify the coding sequence of the human CD24 gene (accession no.: P25063) were as follows: (F): 59-ATGGGC-AGAGCAATGGTGGCC-39 and (R): 59-AGAGTAGAGATG-CAGAG-39.
Mice and tumor cell lines C57BL/6 mice were bred by and purchased from the Central Animal Lab of Nanjing Medical University. The experiments were conducted when the mice were 6-8 weeks old. All experimental protocols used in this study were approved by the Institutional Ethics Committee of Nanjing Medical University.
Hepa1-6, a hepatocellular carcinoma cell line derived from C57BL/6 mice, was purchased from the American Type Culture Collection and maintained in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum (Gibco, Carlsbad, CA, USA). The human CD24 gene was cloned into the EcoRV and NheI sites of the pCDNA3.3 vector. The plasmid pCDNA3.3-CD24 was then electroporated into Hepa1-6 cells. Cells stably expressing CD24 protein were selected using G418 (Sigma, St Louis, MO, USA) at a concentration of 500 mg/ml. Western blotting was performed to detect the expression of human CD24 (Supplementary Figure 1a) and fluorescenceactivated cell sorting was used to sort all G418 selected cells (Supplementary Figure 1b) . The C57BL/6 derived lung cancer cell line Lewis lung carcinoma (LLC), Hepa1-6 and sorted Hepa1-6-CD24 cells were irradiated at 10 000 rads by a c irradiator (Thermo Scientific, Pittsburgh, PA, USA). Proliferation assays were performed to ensure that the irradiated cells could not multiply in vitro. These irradiated cells were used as antigens in the assays described below.
Construction of Lmdd-CD24 vaccines
The shuttle vector PKSV7 containing the dal and dat genes of Bacillus subtilis was used in vaccine construction. The human CD24 gene was amplified by polymerase chain reaction and cloned into PKSV7 at the EcoRV and NotI sites. The PKSV7-CD24 plasmid was electroporated into Lmdd at 10 kV/cm, 400 V and 25 mF. Positive clones were screened on and picked from brain heart infusion (BHI) agar plates (Difco Laboratories, Detroit, MI, USA) supplemented with 20 mg/ml chloramphenicol and 200 mg/ml D-alanine. The PKSV7-CD24 plasmid was forced to insert into the chromosome of Lmdd at 42 uC. After five passages at 42 uC with chloramphenicol and seven passages at 30 uC without chloramphenicol in BHI culture medium, recombinant Lmdd-CD24 strains were picked from a brain heart infusion agar plate. In mice, the attenuated Lmdd-CD24 strain exhibited an LD 50 of about 0. 
In vitro infection of Lmdd-CD24
To investigate the infectivity of the Lmdd-CD24 strain, the human HCC cell lines (7721, Huh-7, HepG2), murine HCC cell line (Hepa1-6) and murine macrophage cell line (Raw264.7) were used. Mouse peritoneal macrophages, isolated as previously described, 31 were also used. All of the above-mentioned cells were cultured at 1.0310 6 cells/well in six-well plates and infected by Lmdd-CD24 strains at multiplicity of infection (MOI)51 : 1. One hour later, uninfected cells were washed away. The infected cells were then lysed in doubledistilled water for three hours and diluted 1 : 1000. The diluted cell suspensions were plated and cultured in BHI plates. CFUs were counted 2-3 days later.
In vivo infection and distribution of Lmdd-CD24 A dose of 5.0310 7 CFUs of Lmdd-CD24 strains was intravenously injected into 6-to 8-week-old mice (n53). On the first and third days after the first immunization, single-cell suspensions were harvested from spleen, liver, kidneys, lungs and brain and cultured on BHI agar plates without chloramphenicol and D-alanine. The CFUs/g for each organ was calculated to determine the differences in organ distribution of the injected Lmdd-CD24. Three days after intravenous injection, the major organs were collected and fixed in formalin for hematoxylin and eosin staining and electron microscopy.
Mouse immunization and tumor challenge C57BL/6 mice were inoculated subcutaneously in the left inguinal region with 5310 6 sorted Hepa1-6-CD24 cells 3 days after or before their first immunization. The mice (n55) then were intravenously injected with 5.0310 7 CFUs of the Lmdd-CD24 or Lmdd strain. As a control, 0.1 ml of PBS was also intravenously injected. In the prophylactic group, mice were immunized 3 days before inoculation with Hepa1-6-CD24 tumor cells, whereas in the therapeutic group, mice were immunized 3 days after tumor challenge. The immunizations were repeated two additional times at 1-week intervals (Supplementary Figure 2) . Four weeks later, mouse splenocytes were isolated from the immunized mice for in vitro assays. Tumor diameter was measured by a caliper every 3 days and recorded as the mean of the longest and narrowest surface lengths. The mice were sacrificed when the average tumor diameter reached 20 mm.
Isolation of splenocytes and tumor-infiltrating lymphocytes
At various time points following immunization, mice were killed and their splenocytes were aseptically isolated. Splenocytes were filtered through cell strainers (BD Falcon, San Jose, CA, USA) and digested with red blood cell lysis buffer (Sigma) to obtain a single-cell suspension. The cells were then centrifuged with Ficoll-Paque Plus (GE Healthcare, Pittsburgh PA, USA) at 2000 r.p.m. for 20 min at room temperature. When centrifugation was complete, four different layers could be observed; the third layer was occupied by lymphocytes. Tumors from mice inoculated with Hepa1-6-CD24 cells were excised and digested with collagenase A and type V hyaluronidase (Sigma) for 45 min at 37 uC. The digested tumor cells were filtered through and centrifuged with Ficoll-Paque Plus as described above to isolate tumor-infiltrating lymphocytes.
ELISPOT assays
Splenocytes were harvested from mice (n53) of the PBS, Lmdd and Lmdd-CD24 groups 1 week after the final immunization and a MACS kit (Miltenyi Biotec, Auburn, CA, USA) was applied to isolate CD8 1 T lymphocytes. CD8 1 T lymphocytes were cultured overnight in 24-well plates at 1.0310 6 cells/well with 20 U/ml recombinant mouse IL-2 and irradiated Hepa1-6-CD24 cells (5310 4 cells/well). Irradiated LLC and Hepa1-6 cells (5310 4 cells/well) were used as controls. The number of splenic interferon (IFN)-c-producing CD8
1 T cells was investigated using a mouse IFN-c ELISPOT kit (R&D, Minneapolis, MN, USA). To count the number of IL-4 and IL-10 secreting cells, splenocytes from the various experimental groups (n510) were also cocultured overnight with 1 ng/ml phorbol myristate acetate. and 0.5 ng/ml ionomycin (Sigma). ELISPOT kits for IL-4 and IL-10 were purchased from R&D (Minneapolis). Assays were conducted according to the manufacturer's directions. Six days after the final vaccination, tumor-infiltrating lymphocytes (TILs) were isolated as previously described and cocultured in 96-well plates (10 7 cells/well) overnight with irradiated Hepa1-6-CD24 cells in the presence of 5 U/ml rmIL-2. The number of CD8
1 T cells isolated from TILs was measured using a CD8 ELISPOT kit (R&D). The plates were counted using an ELISPOT reader, and the results are expressed as spot-forming units per 10 6 cells after subtraction of background spots.
ELISA assay
One week after the final immunization, splenocytes were isolated from mice in the PBS, Lmdd and Lmdd-CD24 groups.
The isolated splenocytes were co-cultured with 20 U/ml rmIL-2 in a six-well plate and stimulated by irradiated Hepa1-6-CD24 cells (5310 4 cells/well) for 3 days. Supernatants were collected from each well, and the concentration of IFN-c in the supernatants was measured using an IFN-c ELISA kit (R&D) according to the manufacturer's manual.
Cell staining and flow cytometry TILs were isolated from mice in the control, prophylactic and therapeutic groups. Regulatory T cells (Tregs) of TILs were identified by flow cytometry after being stained with PECy5.5-conjugated CD4, APC-conjugated CD25 and PE-conjugated Foxp3 (eBioscience, San Diego, CA, USA).
Immunohistochemistry of Tregs
Tumor bearing mice were sacrificed when the even diameter of the tumor reached 20 mm and paraffin-embedded sections of the tumors from the control, prophylactic and therapeutic groups were prepared. Sections were deparaffinized and subjected to heat-induced antigen retrieval using DAKO's target retrieval solution for 25 min. After endogenous peroxidase removal using 3% hydrogen peroxide in methanol for 10 min, samples were incubated twice: first for 15 min with avidinbiotin blocking reagent (Vector, Burlingame, CA, USA) and then for 15 min with protein-blocking reagent (DAKO, Carpinteria, CA, USA). Slides were stained with CD4 (Abcam, San Francisco, CA, USA) and Foxp3 (Abcam) primary antibodies at a dilution of 1 : 100, and immunodetection was performed using a secondary biotinylated polyclonal goat anti-mouse/rat IgG (Sigma). Diaminobenzidine/hydrogen peroxidase was used as the chromogen reagent.
Lactate dehydrogenase (LDH) releasing assay to detect cytotoxicity of CD8 1 T cells from TILs TILs were isolated from tumor bearing mice. CD8
1 T cells from TILs were isolated using a MACS kit (Miltenyi Biotec) and restimulated by irradiated Hepa1-6 or Hepa1-6-CD24 cells overnight to serve as effector cells. Hepa1-6-CD24 cells served as target cells. Effector cells and targeted cells were incubated at various E/T ratios (50 : 1, 25 : 1 and 5 : 1) for 18 h. The LDH level in the supernatants was measured following directions in the manual provided with the LDH kit (Roche, Basel, Switzerland). Spontaneous LDH release from target or effector cells was subtracted from the measured values, and the final results were expressed as the percentage of specific lysis, calculated as (experimental release2target spontaneous release2effector spontaneous release)/(target maximum release2target spontaneous release).
Statistical analysis
Results of each experiment are expressed as the mean6s.d. GraphPad Prism 4.0 software (2005) (GraphPad Software Inc., San Diego, CA, USA) was used to compare the differences between groups by one-way analysis of variance followed by an unpaired t-test. Values of P,0.05 were considered significant. Survival curves were estimated using the Kaplan-Meier method, and significance was evaluated using the log-rank or the x 2 test. (Figure 1b) . Cleaved caspase-9 could process other members of the caspase family, including caspase-3 and caspase-7, to initiate a caspase cascade, which led to apoptosis. Increased levels of cleaved caspase-3 and caspase-9 proteins were observed by western blot in HepG2 and HepG2-pCDNA3.3 cells (Figure 1c ). In the wound-healing test, HepG2-CD24 cells displayed a higher migration rate than cells in the other two groups (Figure 1d ). These results suggest that CD24 can reduce apoptosis and promote migration of tumor cells.
Construction of attenuated Lmdd strains secreting CD24 proteins
The attenuated Lmdd strain was designed to secrete CD24, a surface biomarker of hepatic cancer stem cells. The full coding sequence of CD24 was cloned into the special shuttle vector PKSV7 at the restriction sites of EcoRV and NotI. Hly, a signal-promoter gene, is upstream of the EcoRV enzyme digestion site and can drive the expression of listeriolysin O and of the cloned CD24 gene (Figure 2a ). When the intact plasmid PKSV7-CD24 was electroporated into the cells, the CD24 gene was integrated into the Lmdd chromosome with the help of the sepA gene. Because the vector plasmid PKSV7 contains the dal and dat genes of B. subtilis, successful recombination allowed the Lmdd strains to replicate to a limited extent without a need for exogenous D-alanine. Continuous passage in antibiotic-free medium led the Lmdd-CD24 strains to lose the antibiotic resistance of the shuttle vector plasmid PKSV7. After allelic recombination, secreted proteins were extracted from the culture (Figure 2b ). Stable and durable secretion of CD24 protein is essential for an effective Lmdd-CD24 vaccine. Proteins from the tenth, twentieth, thirtieth and fortieth passages were extracted from the strains and western blot assays showed that Lmdd-CD24 strains stably and reliably secreted CD24 (Figure 2c ). We also compared the colony-forming abilities of the tenth, twentieth, thirtieth and fortieth generations of Lmdd-CD24 to that of and the murine derived hepatocellular carcinoma cell line Hepa1-6, respectively. The murine derived macrophage cell line Raw264.7 and freshly isolated mouse macrophages (M W ) were also used. The cells were cultured in six-well plates at 1.0310 6 cells/well and infected with Lmdd and Lmdd-CD24 at MOI51 : 1. The infected cells were lysed in double-distilled water and diluted 1 : 1000. The dilutions were plated in BHI plates and CFUs were counted. The experiments were performed in triplicate and repeated three times. The data are expressed as the mean6s.d of the CFUs. BHI, brain heart infusion; CFU, colony-forming unit; Lmdd, Listeria monocytogenes strain DdalDdat; MOI, multiplicity of infection.
Lmdd by counting colonies on BHI plates. There were no significant differences in the counts obtained from the genetically modified Lmdd-CD24 vaccine and Lmdd (P.0.05). This result shows that our genetic modification of Lmdd did not alter the stability of the bacteria on passaging (Figure 2d) (Figure 2e ).
In vivo organ distribution and safety of Lmdd-CD24 vaccine after intravenous injection LM is responsible for several foodborne diseases and can even cause severe symptoms such as those associated with listeriolysis. Therefore, it is essential to ensure the safety of the Lmdd-CD24
vaccine. After intravenous injection of 5.0310 7 CFUs of Lmdd-CD24, most bacteria were distributed to distant organs, primarily translocated into the spleen and liver and replicated in macrophages and hepatocytes, where they can remain for about 3 days. In this assay, some major organs of the infected mice, including spleen, liver, lung and brain, were collected. CFUs/g on the first and third days after intravenous injection was calculated for these organs. The results showed that the infected Lmdd-CD24 mainly resided in the spleen and liver, whereas only a small amount of bacteria was found in the kidneys and lungs and none was found in the brain. Using electron microscopy, numerous Lmdd-CD24 strains were observed in the spleen (Figure 3a) . Although Lmdd-CD24 is attenuated by several genetic modifications, it is not clear whether it can cause serious organ injuries and untoward effects such as listeriolysis, meningitis and even death after intravenous injection. To investigate the safety of this vaccine, 5.0310 7 CFUs of Lmdd-CD24 vaccine was intravenously administered. Three days later, the major organs (liver, spleen and kidney) of the immunized mice were collected and fixed in formaldehyde. Hematoxylin and eosin staining showed that there was only a weak inflammatory response and no structural damage or necrosis in the liver. The Figure 3 Organ distribution of Lmdd-CD24 strains after intravenous injection. (a) Lmdd-CD24 strains (5310 7 CFUs) were intravenously administered to mice, and CFUs/g of Lmdd-CD24 in various organs were counted on the first and third days after injection. Homogenized tissues from different mouse organs (spleen, liver, kidneys, lungs and brain) were placed on BHI plates and incubated at 37 uC overnight. Using electron microscopy, large numbers of Lmdd-CD24 strains were observed in spleen tissue. Experiments were repeated three times. The data are expressed as the mean6s.d of the CFUs. (b) The safety of attenuated Lmdd-CD24 bacteria in mice assessed by hematoxylin and eosin staining. Immunized mice were sacrificed 3 days after intravenous administration of 5.0310 7 CFUs of Lmdd-CD24. To investigate possible injuries, vital organs (liver, spleen and kidney) were collected for hematoxylin and eosin staining. Slight inflammatory responses were observed in some hepatocytes. The hepatic central venous system was intact and no tissue necrosis or structural damage was seen. In the spleen, only infiltration of lymphocytes occurred. Compared to the normal control, mild injuries were observed in the kidney. These pictures show representative tissue samples from three mice in the vaccinated and normal groups. Black arrows indicate sites of inflammation or lymphocyte infiltration. BHI, brain heart infusion; CFU, colony-forming unit; Lmdd, Listeria monocytogenes strain DdalDdat.
spleen exhibited only infiltration of lymphocytes, whereas in the kidneys, mild injuries were evident compared with the normal control (Figure 3b) . No deaths of mice were observed after intravenous injection. These results confirm that the Lmdd-CD24 vaccine is safe and reliable and that it has potential for clinical application.
Lmdd-CD24 can induce Th1 and Th2 cell-mediated immune responses
The immunotherapeutic efficacy of cancer vaccines depends largely on the promotion of antigen-specific immune responses. Due to its unique characteristic of spreading from cell to cell without entering the outside environment and its ability to present antigens through the MHC class I pathway, 32 the Lmdd-CD24 vaccine induces an immune response characterized by Th1-and Th2-type cell activation. 33 To objectively assess the immunological role of Lmdd-CD24, we measured the number of IFN-c-producing CD8
1 T cells, the IFN-c level in culture supernatants and the levels of IL-4 and IL-10 cytokines secreted by Th2 cells. IFN-c is critical for innate and adaptive immune responses to intracellular bacterial infections and tumor control. After coculture of splenic CD8
1 T lymphocytes isolated by a MACS kit with irradiated LLC, Hepa1-6 and Hepa1-6-CD24 cells, the Lmdd-CD24 immunized group stimulated with irradiated Hepa1-6-CD24 cells displayed the most IFN-c-producing CD8 1 T cells (453655 SFC/10 6 cells) and the highest level of IFN-c (13346152 pg/ml) in the cell supernatants. Splenocytes from mice in the PBS or Lmdd immunized groups produced little IFN-c even after stimulation by irradiated Hepa1-6-CD24 cells (Figure 4a and b) . Th1 cells can produce IFN-c, whereas Th2 cells mainly secret cytokines such as IL-4, IL-5, IL-6 and IL-10. One week after the final immunization, we isolated splenocytes from each group and measured the number of cells secreting IL-4 and IL-10 cytokines by ELISPOT. Mice in the Lmdd-CD24 vaccinated group displayed more IL-4-and IL-10-secreting Th2 cells than the mice in the other two groups (P,0.01) (Figure 4c ). These results suggest that our recombinant and attenuated Lmdd-CD24 vaccine may elicit both Th1 and, to some extent, Th2 cell responses.
Lmdd-CD24 causes regression of inoculated Hepa1-6-CD24 tumors in mice To study the prophylactic and therapeutic efficacy of the Lmdd-CD24 vaccine, we subcutaneously inoculated 5310 splenic T lymphocytes in different groups. Splenocytes harvested from mice in the PBS, Lmdd and Lmdd-CD24 groups (n53) were sorted by a CD8 MACS kit, cultured overnight in 24-well plates at 5310 6 cells/well with 20 U/ml rmIL-2 and stimulated by irradiated Hepa1-6-CD24 cells. Splenocytes were also co-cultured with irradiated LLC and Hepa1-6 cells as a control. Using the IFN-c ELISPOT kit, the Lmdd-CD24 vaccinated group displayed more IFN-c producing CD8
1 T cells than other groups after stimulation by irradiated Hepa1-6-CD24 cells. When stimulated by irradiated LLC or Hepa1-6 cells, no obvious spot-forming units were observed in the PBS, Lmdd and Lmdd-CD24 groups. *P,0.05, **P,0.01. (b) ELISA assay to detect IFN-c levels in supernatants of stimulated splenocytes from various immunized groups. Splenocytes (n53) were cocultured with irradiated Hepa1-6-CD24 cells for 3 days and the culture supernatants were harvested for ELISA assay. Irradiated LLC and Hepa1-6 cells were used as controls. After stimulation by irradiated Hepa1-6-CD24 cells, splenocytes from the Lmdd-CD24 vaccinated group produced the highest levels of IFN-c. When stimulated by irradiated control cells (LLC and Hepa1-6), no increased levels of IFN-c were detected in any group. The assays were repeated at least three times in triplicate. The data are expressed as the mean6s.d. *P,0.05, **P,0.01. (c) ELISPOT assay to measure the number of IL-4-and IL-10-secreting Th2 cells. Splenocytes were harvested from control or immunized groups (n510) 1 week after immunization and cocultured in the presence of 1 ng/ml PMA and 0.5 ng/ml ionomycin overnight. The levels of cytokines (IL-4 and IL-10) secreted by the Th2 cells of each group were measured by ELISPOT assays. Individual and mean values are shown. IFN, interferon; LLC, Lewis lung carcinoma; Lmdd, Listeria monocytogenes strain DdalDdat; PBS, phosphate-buffered saline; PMA, phorbol myristate acetate. the prophylactic and therapeutic groups, Lmdd-CD24 significantly reduced the size and slowed the growth of the tumors compared to PBS or Lmdd (Figure 5a and b) (P,0.05). Evaluation of the tumor-free survival of mice showed that the Lmdd-CD24 vaccinated mice in both the prophylactic and the therapeutic groups achieved longer survival than the mice in the control group (Figure 5c and d) .
Immunological roles of Tregs and CD8
1 T cells isolated from TILs in preventing tumor regression caused by the Lmdd-CD24 vaccine A variety of mechanisms affect cancer progression and regression. Recent discoveries have shed some light on a population of cells called Tregs, which are characterized by co-expression of CD4 and the IL-2 receptor a-chain (CD25). We initially isolated TILs from tumors stained with CD4, CD25 and forkhead box (Fox)p3 antibodies and analyzed these cells by flow cytometry. By comparing the percentages of Tregs isolated from mice in the different experimental groups, we found that mice in the control group had more Tregs than those in the prophylactic and therapeutic groups (8.414%60.268% in the control group, 3.612%60.280% in the prophylactic group, 3.392%60.288% in the therapeutic group) (Figure 6a) . A similar result was obtained in the immunohistochemistry assay. Lower positive staining levels of CD4 2 and Foxp3 2 double positive cells were observed in the prophylactic and therapeutic groups (Figure 6b ). These results suggest that the Lmdd-CD24 vaccine significantly reduces the level of Treg cells, which are negative regulators in anti-tumor immunity. TILs from the prophylactic and therapeutic groups were cocultured with irradiated Hepa1-6-CD24 cells and the number of CD8 1 T cells from TILs was measured by ELISPOT assay. Lmdd-CD24-vaccinated mice had more CD8
1 T cells isolated from TILs in their tumor areas than did the other two groups of mice (P,0.05) (Figure 6c ). This finding suggests that the Lmdd-CD24 vaccine can induce antigen-specific CD8
1 T cells from TILs to participate in anti-tumor immunity at local tumor sites. In addition, the LDH-releasing assay demonstrated that restimulated CD8
1 T cells from TILs in tumor areas could effectively eliminate CD24-expressing target cells (Figure 6d) . Thus, the Lmdd-CD24 vaccine reduces the recruitment of Tregs and induces the presence of cytotoxic CD8
1 T cells among the TILs isolated from tumor areas.
DISCUSSION
Hepatocellular carcinoma, the fifth most common cancer worldwide, represents a serious threat to public health. The use of specific treatments for HCC, such as resection, liver transplantation and percutaneous ablation, varies geographically. 34 Despite the availability of these treatment methods, chemoresistance, metastasis and recurrence result in poor prognosis in many HCC patients. The cancer stem cell hypothesis posits that cancers are maintained in a hierarchical organization of 'cancer stem cells' that can rapidly differentiate into amplifying cells and differentiated tumor cells. 35 CSCs can initiate and sustain tumor growth and are responsible for the prognosis of cancers. 36 CD24 is a newly discovered biomarker that is overexpressed in hepatic CSCs and is closely related to HCC chemoresistance, metastasis and recurrence. CD24-positive HCC cells are critical for the maintenance, self-renewal and differentiation of tumors and may significantly impact the clinical outcome of HCC patients. Hence, if CD24-positive cells could be specifically and effectively targeted, chemoresistance, metastasis and recurrence of HCC might be prevented. By incorporation into a suitable vector, the CD24 protein could be effectively delivered and used to elicit a strong innate and adaptive immune response. With the development of microbiology and immunology, pathogens could be inactivated and attenuated for vaccines. LM, an intracellular parasite, is an eligible candidate for such a vaccine vector. For clinically used vaccines, safety is an essential priority that must be seriously considered. In this study, attenuated LM, which is herein referred to as Lmdd, was applied as a vaccine vector to secrete tumor-associated antigen. It was attenuated by deletion of the dal and dat genes, which are essential for the synthesis of D-alanine. Upon introduction of the shuttle vector PKSV7, which contains the B. subtilis dal and dat genes, Lmdd replicated only to a limited extent and did not cause serious injury. LM could also be attenuated by deletion of the actA/plcB genes and retained its immunogenicity. The actA gene is responsible for actin polymerization, organelle movement within eukaryotic cells and intercellular spread. 37 The plcB gene encodes a phospholipase or lecithinase 38 and has been shown to be very important for secondary vacuolar escape. 39 LMDactA/ plcB was less attenuated than Lmdd, as shown by the fact that its LD 50 was around 1.47310 4 CFUs. The virulence of LM was reduced by deletion of either the dal/dat or the actA/plcB genes. These features may be clinically applied in the future. After intravenous injection, Lmdd-CD24 was rapidly phagocytosed by immune cells, such as dendritic cells and macrophages, and could elicit both CD4
1 and CD8 1 T-cell responses without obvious toxicity. Proteins secreted by Lmdd could be presented through the MHC-I molecular pathway in its intracellular phase, as well as directly through the MHC-II molecular pathway. For these reasons, Lmdd was chosen for delivery of the hepatic CSC biomarker CD24. The Lmdd-CD24 cancer vaccine represents a novel immunotherapeutic agent for the prevention and treatment of HCC chemoresistance, metastasis and recurrence.
When Lmdd-CD24 strains were intravenously administered into mice, the injected bacteria replicated and accumulated in peripheral lymphocytes. The injected Lmdd-CD24 strains were mainly distributed to the spleen, liver and lung and did not cause serious organ injuries. By presenting the CD24 protein, Lmdd-CD24 induced a specific T cell-mediated immune response. IFN-c is a crucial cytokine in Th1 cell-mediated immunity against tumor cell proliferation. After intravenous administration of Lmdd-CD24, the number of IFN-c-producing CD8 1 T lymphocytes and the level of IFN-c were significantly increased. Using splenocyte ELISPOT assays, we found that Lmdd-CD24 strains stimulated the host to produce low levels of Th2 cell-secreted cytokines such as IL-4 and IL-10. However, this weak Th2-cell-mediated immune response may be essential and may play an auxiliary role in anti-tumor immunity.
Foxp3
1 Tregs. Tumor tissues were fixed in formalin and paraffin-embedded sections were prepared and stained with CD4 or Foxp3 antibodies. The IOD of each section was calculated with the aid of computer software for five fields (3100). Comparison of the control, prophylactic and therapeutic groups was performed using Image-Pro Plus software (version 6.0). Data were expressed as the mean6s.d. (c) ELISPOT assay measuring the number of CD8 1 T cells isolated from TILs. When the mice from each group were sacrificed, TILs were isolated. CD8 ELISPOT assay demonstrated that the Lmdd-CD24 vaccinated mice in the prophylactic and therapeutic groups recruited more CD8 1 T cells from TILs in the tumor area than did the mice in the other two groups. *P,0.05, **P,0.01. (d) LDH-releasing assay measuring the cytotoxicity of CD8 1 T cells isolated from TILs against target cells. CD8
1 T cells from TILs were isolated by MACS after the mice were killed and restimulated by irradiated Hepa1-6 or Hepa1-6-CD24 cells to serve as effector cells. The effector cells and target cells (Hepa1-6-CD24) were incubated for 18 h at ratios of 50 : 1, 25 : 1 and 5 : 1. The LDH levels in the cell culture supernatants were measured using an LDH detection kit as directed by the manufacturer. The data are presented as the mean6s.d. Student's t-test and Image-Pro Plus software (version 6.0) were used to analyze the data. *P,0.05, **P,0.01. IOD, intensity of the optical density; LDH, Lactate dehydrogenase; Lmdd, Listeria monocytogenes strain DdalDdat; TIL, tumor-infiltrating lymphocyte; Treg, regulatory T cell.
Recombinant LM has been shown to have an exceptional capacity to induce anti-tumor immunity to tumor-associated antigens such as HPV16 E7, 40 influenza virus NP3 41 and HIV-1 gag. 42 Kim et al. found that LM based vaccines could not only remove primary tumors, but also eliminate metastases and residual tumor cells. 43 In this research, Lmdd-CD24 vaccine caused the regression of inoculated Hepa1-6-CD24 tumors, prevented tumor occurrence and growth in the prophylactic and therapeutic groups and increased tumor-free survival of the mice. This might be explained by the suppressed recruitment of Tregs in the immunized mice and the stimulation of CD8 1 T cells isolated from TILs in local tumor areas. CD4
1 CD25 1 Foxp3 1 Tregs had an adverse effect on the prognosis of many tumors, 44 including HCC. 45 In the current study, we found a decrease of CD4 1 CD25 1 Foxp3 1 Tregs in tumors of mice that were vaccinated with Lmdd-CD24. In ELISPOT and LDH-release assays, Lmdd-CD24 vaccine increased the number of CD8 1 T cells isolated from TILs. These results indicate that the Lmdd-CD24 vaccine can suppress the recruitment and differentiation of Tregs in tumors and stimulate CD8
1 T cells from TILs, thus reducing tumor size and extending host survival. The animal model described above differs greatly from hepatocellular carcinoma in humans. However, our goal in establishing a tumor bearing animal model by inoculating Hepa1-6-CD24 cells, which overexpress CD24 protein, is to show that Lmdd-CD24 strains could effectively induce the regression of inoculated tumors and elicit anti-tumor immunity. The results demonstrate that Lmdd-CD24 strains can specifically target tumor cells that express CD24 antigen. Vaccine adjuvants, such as cyclophosphamide and granulocyte macrophage colony-stimulating factor, can enhance the anti-tumor effects of the vaccines, and recently curcumin was demonstrated to improve the therapeutic efficacy of LM. 46 Based on these findings, we hypothesize that the prophylactic and therapeutic effects of Lmdd-CD24 vaccine might also be enhanced by some adjuvants.
In conclusion, Lmdd-CD24 can stably secrete the CD24 protein, a hepatic CSC marker, as a tumor-associated antigen to elicit a specific immune response. Lmdd-CD24 is a safe and effective vaccine that reduces tumor size and extends tumorfree survival in mice. The Lmdd-CD24 strain has the potential to prevent HCC chemoresistance, metastasis and recurrence and merits further investigation as a cancer vaccine vector for future clinical application.
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